ICON plc (NASDAQ: ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup.
DUBLIN--(BUSINESS WIRE)-- ICON plc (ICLR), (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced the expansion of its portfolio of ...
The Company plans to extend its Phase II trial of HT-001 in Cancer Patients with skin toxicities in European Union (EU) Countries "We are delighted with the addition of clinical sites in the EU and ...
DUBLIN--(BUSINESS WIRE)-- ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been rated as one of the top-performing contract research ...
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation today announced the discontinuation of its Phase 3 ICoN-1 clinical trial evaluating MNKD-101, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results